Rebinyn and Refixia market set for steady growth through 2035
The market for Rebinyn and Refixia is gaining momentum as hemophilia B diagnosis rises, healthcare spending climbs and demand grows for more convenient treatment options. North America leads today, while Asia-Pacific is expected to be the fastest-growing region through the forecast period.
Why it matters: - Rebinyn and Refixia are long-acting factor IX therapies used to prevent and treat bleeding in hemophilia B. - Wider use of extended half-life biologics can reduce injection frequency and improve treatment adherence. - Growth in this market reflects broader demand for more convenient home-based hemophilia care.
What happened: - The Business Research Company published its Rebinyn and Refixia Global Market Report 2026, covering market size, trends and a forecast from 2026 to 2035. - The report says the market is being driven by advances in hemophilia B treatment and rising patient awareness. - A free sample of the report is available here. - The full report is available here.
The details: - Rebinyn is also marketed as Refixia in some territories. - The drug is designed to treat and prevent bleeding episodes in patients with hemophilia B. - The extended half-life formulation helps reduce how often patients need injections. - Rebinyn is used for routine prophylaxis, on-demand bleeding management and surgical procedures. - Historical market growth was supported by recombinant factor IX therapy advances, higher hemophilia B diagnosis rates, early adoption of long-acting factor products, broader access to specialized hemophilia care centers and regulatory approvals for extended half-life biologics. - Future growth is expected to come from demand for convenient hemophilia management, wider home-based treatment, more investment in next-generation clotting factors, a stronger focus on quality of life and biologic drug engineering innovation. - Rising hemophilia prevalence is a key driver because more diagnoses mean more treated patients. - Advanced genetic testing has helped increase confirmed hemophilia cases. - In April 2025, Pfizer reported that the UK hemophilia A and B patient population surpassed 11,800. - Growing healthcare spending is also supporting access to therapies such as Rebinyn and Refixia. - The UK Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023. - The same report showed long-term health and social care costs rose 2.8% in real terms in 2022. - In 2025, North America held the largest share of the market. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa.
Between the lines: - The market is benefiting from a shift toward treatment models that fit more easily into patients' daily lives. - Higher diagnosis rates and better specialty care access are expanding the addressable patient pool. - The report's broader analytics, including TAM analysis and market attractiveness scoring, suggest vendors are competing in a more data-driven market.
What's next: - The forecast period through 2035 points to continued demand for extended half-life clotting factors. - Further gains will likely depend on broader access to biologics, stronger specialty care networks and continued adoption of home treatment models. - Asia-Pacific's growth will hinge on diagnosis expansion, healthcare access and investment in biologic therapies. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspot infographics and updated trend analysis. - More information is available from the company's social channels, including LinkedIn and the company page.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
UK Post Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.